RetourAFB
acid-fast bacilli
AHD
advanced HIV disease
AIDS
acquired immunodeficiency syndrome
ART
antiretroviral therapy
CC
critical concentration
CI
confidence interval
CSF
cerebrospinal fluid
DNA
deoxyribonucleic acid
DR-TB
drug-resistant tuberculosis
DST
drug susceptibility testing
EQA
external quality assessment
FIND
Foundation for Innovative New Diagnostics
FL-LPA
line probe assay for first-line drugs
GDG
guideline development group
GLI
Global Laboratory Initiative
HIV
human immunodeficiency virus
Hr-TB
isoniazid-resistant, rifampicin-susceptible TB
IT
information technology
LAM
lipoarabinomannan
LAMP
loop-mediated isothermal amplification
LF-LAM
lateral flow lipoarabinomannan assay
LoD
limit of detection
LPA
line probe assay
MDR/RR-TB
multidrug- or rifampicin-resistant tuberculosis
MDR-TB
multidrug-resistant tuberculosis
MGIT
Mycobacterial Growth Indicator Tube
MIC
minimal inhibitory concentration
MoH
ministry of health
MTBC
Mycobacterium tuberculosis complex
mWRD
molecular WHO-recommended rapid diagnostic test
NAAT
nucleic acid amplification test
NGS
next-generation sequencing
NTP
national TB programme
NTRL
national TB reference laboratory
PCR
polymerase chain reaction
PLHIV
people living with HIV/AIDS
QA
quality assurance
QC
quality control
RRDR
rifampicin-resistance-determining region
RR-TB
rifampicin-resistant tuberculosis
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
SL-LPA
line probe assay for second-line drugs
SOP
standard operating procedure
SRL
supranational reference laboratory
TB
tuberculosis
TWG
technical working group
USA
United States of America
WGS
whole-genome sequencing
WHO
World Health Organization
WHO/GTB
WHO Global TB Programme
WHO PQ
WHO Prequalification Unit
WRD
WHO-recommended rapid diagnostic test
XDR-TB
extensively drug-resistant tuberculosis